Sapio Sciences Collaborates with IQVIA to Facilitate Broad Adoption of Genomics Sequencing

Sapio’s unified lab informatics platform is supporting genomics collaborations between IQVIA and global government and public health entities.

FOR IMMEDIATE RELEASE

BALTIMORE, January 9, 2024 – Sapio Sciences, the science-aware™ lab informatics platform, today announced its collaboration with IQVIA, a leading global provider of advanced analytics, technology solutions, and clinical research services to the pharmaceutical and broader life sciences industry. 

Through this collaboration, Sapio will provide its all-in-one, science-aware platform that combines an electronic laboratory notebook (ELN), laboratory information management system (LIMS), and a scientific data cloud to collaborators working with IQVIA on public health initiatives. Genomics will be used to advance patient care and better prevent, diagnose and treat disease. IQVIA has collaborated with multiple leading national genomics centers to manage and curate real-world data with genomics insights on patient populations. The integration of Sapio’s platform will help scientists manage sequencing workflows and data to visualize and analyze data within a single environment.

“IQVIA provides deep healthcare and life sciences domain expertise to help our collaborators around the world unlock the potential of genomics to provide insight on disease,” said Joanne Hackett, Vice President of Genomic and Precision Medicine at IQVIA. “We’re equally committed to equipping scientists to manage and make sense of the unprecedented volumes and complexity of data generated by modern sequencing workflows. Through this collaboration with Sapio, scientists gain powerful, science-aware tools to help propel their research and advance patient care.” 

“We’ve been thrilled to collaborate with IQVIA on the work underway at national genome centers,” said Kevin Cramer, President and CEO of Sapio Sciences. “This extension of our partnership will make our unified and simplified platform available to power similar future collaborations and afford us the chance to drive scientific breakthroughs in the understanding of genomic science.”

About IQVIA

IQVIA (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry. IQVIA creates intelligent connections across all aspects of healthcare through its analytics, transformative technology, big data resources, and extensive domain expertise. IQVIA Connected Intelligence™ delivers powerful insights with speed and agility—enabling customers to accelerate the clinical development and commercialization of innovative medical treatments that improve healthcare outcomes for patients. With approximately 87,000 employees, IQVIA conducts operations in more than 100 countries. 

IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures.

To learn more, visit www.iqvia.com.

About Sapio Sciences

Sapio Sciences’ mission is to improve life in the lab – because science is complex, Sapio makes technology simple. Sapio is a global business offering an all-in-one science-aware (TM) lab informatics platform combining cloud-based LIMS, ELN, and Jarvis data solutions. 

Sapio serves some of the largest global and niche brands, including biopharma, CRO’s and clinical diagnostic labs across NGS genomic sequencing, bioanalysis, bioprocessing, stability, clinical, histopathology, drug research, and in vivo studies. 

Customers love Sapio’s platform because it is robust, scalable, and with no-code configuration, can quickly adapt to meet unique needs. For more information visit www.sapiosciences.com and follow us on Linkedin here.

PreviousNext